相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Demystifying solid targets: Simple and rapid distribution-scale production of [68Ga]GaCl3 and [68Ga]Ga-PSMA-11
Johan Svedjehed et al.
NUCLEAR MEDICINE AND BIOLOGY (2022)
An Improved 211At-Labeled Agent for PSMA-Targeted α-Therapy
Ronnie C. Mease et al.
JOURNAL OF NUCLEAR MEDICINE (2022)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals
Teja Muralidhar Kalidindi et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)
PSMA-targeted low-molecular double conjugates for diagnostics and therapy
Stanislav A. Petrov et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Targeted Alpha Therapy: Progress in Radionuclide Production, Radiochemistry, and Applications
Bryce J. B. Nelson et al.
PHARMACEUTICS (2021)
Update from PSMA-SRT Trial NCT03582774: A Randomized Phase 3 Imaging Trial of Prostate-specific Membrane Antigen Positron E-mission Tomography for Salvage Radiation Therapy for Prostate Cancer Recurrence Powered for Clinical Outcome
Jeremie Calais et al.
EUROPEAN UROLOGY FOCUS (2021)
UpFrontPSMA: a randomized phase 2 study of sequential 177Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naive prostate cancer (clinical trial protocol)
Nattakorn Dhiantravan et al.
BJU INTERNATIONAL (2021)
Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study
Michael J. Morris et al.
CLINICAL CANCER RESEARCH (2021)
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
Michael S. Hofman et al.
LANCET (2021)
Copper-67 radioimmunotheranostics for simultaneous immunotherapy and immuno-SPECT
Guiyang Hao et al.
SCIENTIFIC REPORTS (2021)
Preclinical and Clinical Status of PSMA-Targeted Alpha Therapy for Metastatic Castration-Resistant Prostate Cancer
Asta Juzeniene et al.
CANCERS (2021)
Evaluation of 18F-DCFPyL PSMA PET/CT for Prostate Cancer: A Meta-Analysis
Ke-Hao Pan et al.
FRONTIERS IN ONCOLOGY (2021)
A prostate-specific membrane antigen (PSMA)-targeted prodrug with a favorable in vivo toxicity profile
Srikanth Boinapally et al.
SCIENTIFIC REPORTS (2021)
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Oliver Sartor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
The Role of Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Primary Staging of Newly Diagnosed Prostate Cancer: A Systematic Review of the Literature
Raisa S. Abrams-Pompe et al.
EUROPEAN UROLOGY ONCOLOGY (2021)
[68Ga]Ga-P16-093 as a PSMA-Targeted PET Radiopharmaceutical for Detection of Cancer: Initial Evaluation and Comparison with [68Ga]Ga-PSMA-11 in Prostate Cancer Patients Presenting with Biochemical Recurrence
Mark A. Green et al.
MOLECULAR IMAGING AND BIOLOGY (2020)
PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study
Daniel P. Petrylak et al.
PROSTATE (2020)
Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients
Madhav Prasad Yadav et al.
CLINICAL NUCLEAR MEDICINE (2020)
Dose-escalation results of a phase I study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).
Scott T. Tagawa et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Radiation Dosimetry in Lu-177-PSMA-617 Therapy Using a Single Posttreatment SPECT/CT Scan: A Novel Methodology to Generate Time- and Tissue-Specific Dose Factors
Price A. Jackson et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
Development of 18F-Fluoroglycosylated PSMA-Ligands with Improved Renal Clearance Behavior
Roman Potemkin et al.
MOLECULAR PHARMACEUTICS (2020)
Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings
Felipe de Galiza Barbosa et al.
CANCER IMAGING (2020)
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study
Michael S. Hofman et al.
LANCET (2020)
Preclinical Evaluation of a High-Affinity Sarcophagine-Containing PSMA Ligand for 64Cu/67Cu-Based Theranostics in Prostate Cancer
James M. Kelly et al.
MOLECULAR PHARMACEUTICS (2020)
PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy
Wallace Jones et al.
CANCERS (2020)
Glycosylated Nanoparticles for Cancer-Targeted Drug Delivery
Sergio Andres Torres-Perez et al.
FRONTIERS IN ONCOLOGY (2020)
Synthesis and Evaluation of 68Ga- and 177Lu-Labeled (R)- vs (S)-DOTAGA Prostate-Specific Membrane Antigen-Targeting Derivatives
Ruiyue Zhao et al.
MOLECULAR PHARMACEUTICS (2020)
Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
Michael Sun et al.
CUREUS JOURNAL OF MEDICAL SCIENCE (2020)
Targeting prostate cancer: Prostate-specific membrane antigen based diagnosis and therapy
Till Wuestemann et al.
MEDICINAL RESEARCH REVIEWS (2019)
First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer
Jie Zang et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial
Wolfgang P. Fendler et al.
JAMA ONCOLOGY (2019)
Review of 18F-Fluciclovine PET for Detection of Recurrent Prostate Cancer
Mariya Gusman et al.
RADIOGRAPHICS (2019)
Electrostatic Effects Accelerate Decatungstate-Catalyzed C-H Fluorination Using [18F]- and [19F]NFSI in Small Molecules and Peptide Mimics
Zheliang Yuan et al.
ACS CATALYSIS (2019)
Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer
Daniel P. Petrylak et al.
PROSTATE (2019)
Clinical impact of PSMA-based 18F-DCFBC PET/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy
Esther Mena et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Intraindividual Comparison of 18F-PSMA-1007 and 18F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study
Frederik L. Giesel et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
A Perspective on the Evolving Story of PSMA Biology, PSMA-Based Imaging, and Endoradiotherapeutic Strategies
Denise S. O'Keefe et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Effects of Linker Modification on Tumor-to-Kidney Contrast of 68Ga-Labeled PSMA-Targeted Imaging Probes
Hsiou-Ting Kuo et al.
MOLECULAR PHARMACEUTICS (2018)
Synthesis and preclinical evaluation of novel 18F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with 18F-DCFPyl and 18F-PSMA1007
Stephanie Robu et al.
EJNMMI RESEARCH (2018)
PSMA Theranostics: Current Status and Future Directions
Kambiz Rahbar et al.
MOLECULAR IMAGING (2018)
2-Aminoadipic Acid-C(O)-Glutamate Based Prostate-Specific Membrane Antigen Ligands for Potential Use as Theranostics
Ryo Nakajima et al.
ACS MEDICINAL CHEMISTRY LETTERS (2018)
German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients
Kambiz Rahbar et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Preclinical Evaluation of 18F-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer Imaging
Jens Cardinale et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer
Mike Sathekge et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
Diagnostic Performance of Prostate Imaging Reporting and Data System Version 2 for Detection of Prostate Cancer: A Systematic Review and Diagnostic Meta-analysis
Sungmin Woo et al.
EUROPEAN UROLOGY (2017)
PSMA-Targeted Theranostic Nanocarrier for Prostate Cancer
Orielyz Flores et al.
THERANOSTICS (2017)
Synthesis, Positron Emission Tomography Imaging, and Therapy of Diabody Targeted Drug Lipid Nanoparticles in a Prostate Cancer Murine Model
Patty Wong et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2017)
213Bi-Labeled Prostate-Specific Membrane Antigen-Targeting Agents Induce DNA Double-Strand Breaks in Prostate Cancer Xenografts
Julie Nonnekens et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2017)
[18F]Fluorobenzoyllysinepentanedioic Acid Carbamates: New Scaffolds for Positron Emission Tomography (PET) Imaging of Prostate-Specific Membrane Antigen (PSMA)
Xing Yang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
[18F]Fluoroethyl Triazole Substituted PSMA Inhibitor Exhibiting Rapid Normal Organ Clearance
Ying Chen et al.
BIOCONJUGATE CHEMISTRY (2016)
Design of a Small-Molecule Drug Conjugate for Prostate Cancer Targeted Theranostics
Amit Kumar et al.
BIOCONJUGATE CHEMISTRY (2016)
18F-FACBC (anti1-amino-3-18F-fluorocyclobutane-1-carboxylic acid) versus 11C-choline PET/CT in prostate cancer relapse: results of a prospective trial
Cristina Nanni et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2016)
Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors
Martina Benesova et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
225Ac-PSMA-617 for PSMA-Targeted a-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer
Clemens Kratochwil et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Systemic Radioligand Therapy with 177Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer
Matthias M. Heck et al.
JOURNAL OF UROLOGY (2016)
Glycosylation, an effective synthetic strategy to improve the bioavailability of therapeutic peptides
Shayli Varasteh Moradi et al.
CHEMICAL SCIENCE (2016)
A phase 2 study of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC) following abiraterone and/or enzalutamide (abi/enz).
Daniel Peter Petrylak et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions
Ali Afshar-Oromieh et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer
Martina Benesova et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies
Martina Weineisen et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status
Susanne Lutje et al.
THERANOSTICS (2015)
A Small-Molecule Drug Conjugate for the Treatment of Carbonic Anhydrase IX Expressing Tumors
Nikolaus Krall et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2014)
Enantiopure bifunctional chelators for copper radiopharmaceuticals - Does chirality matter in radiotracer design?
Ajay N. Singh et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2014)
Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy
Christian M. Zechmann et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
A Prospective Pilot Study of 89Zr-J591/Prostate Specific Membrane Antigen Positron Emission Tomography in Men with Localized Prostate Cancer Undergoing Radical Prostatectomy
Joseph R. Osborne et al.
JOURNAL OF UROLOGY (2014)
Improving the biodistribution of PSMA-targeting tracers with a highly negatively charged linker
Steve S. Huang et al.
PROSTATE (2014)
Design and preclinical evaluation of a 99mTc-labelled diabody of mAb J591 for SPECT imaging of prostate-specific membrane antigen (PSMA)
Florian Kampmeier et al.
EJNMMI RESEARCH (2014)
Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer
Martina Weineisen et al.
EJNMMI RESEARCH (2014)
The potential and hurdles of targeted alpha therapy - clinical trials and beyond
Jorgen Eigqvist et al.
FRONTIERS IN ONCOLOGY (2014)
A phase 2 trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC).
Daniel Peter Petrylak et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Small Targeted Cytotoxics: Current State and Promises from DNA-Encoded Chemical Libraries
Nikolaus Krall et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2013)
Aptamer-conjugated and doxorubicin-loaded unimolecular micelles for targeted therapy of prostate cancer
Wenjin Xu et al.
BIOMATERIALS (2013)
Optimization of Initial Prostate Biopsy in Clinical Practice: Sampling, Labeling and Specimen Processing
Marc A. Bjurlin et al.
JOURNAL OF UROLOGY (2013)
A Multivalent Approach of Imaging Probe Design To Overcome an Endogenous Anion Binding Competition for Noninvasive Assessment of Prostate Specific Membrane Antigen
Guiyang Hao et al.
MOLECULAR PHARMACEUTICS (2013)
Immunogenicity assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine
Montserrat Carrasco-Triguero et al.
BIOANALYSIS (2013)
68Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging
Matthias Eder et al.
BIOCONJUGATE CHEMISTRY (2012)
Glutamate Carboxypeptidase II: An Overview of Structural Studies and Their Importance for Structure-Based Drug Design and Deciphering the Reaction Mechanism of the Enzyme
J. Pavlicek et al.
CURRENT MEDICINAL CHEMISTRY (2012)
Choline PET and PET/CT in Primary Diagnosis and Staging of Prostate Cancer
S. Schwarzenboeck et al.
THERANOSTICS (2012)
The Orally Active Glutamate Carboxypeptidase II Inhibitor E2072 Exhibits Sustained Nerve Exposure and Attenuates Peripheral Neuropathy
Krystyna M. Wozniak et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
2-(3-{1-Carboxy-5-[(6-[18F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [18F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate Cancer
Ying Chen et al.
CLINICAL CANCER RESEARCH (2011)
Tumor Physiology and Charge Dynamics of Anticancer Drugs: Implications for Camptothecin-based Drug Development
D. J. Adams et al.
CURRENT MEDICINAL CHEMISTRY (2011)
In Vitro and In Vivo Responses of Advanced Prostate Tumors to PSMA ADC, an Auristatin-Conjugated Antibody to Prostate-Specific Membrane Antigen
Xinning Wang et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen
Michael J. Evans et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
PET with Non-Standard Nuclides
Guiyang Hao et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2010)
Prostate-Specific Membrane Antigen Targeted Imaging and Therapy of Prostate Cancer Using a PSMA Inhibitor as a Homing Ligand
Sumith A. Kularatne et al.
MOLECULAR PHARMACEUTICS (2009)
Pseudoirreversible Inhibition of Prostate-Specific Membrane Antigen by Phosphoramidate Peptidomimetics
Tiancheng Liu et al.
BIOCHEMISTRY (2008)
N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC:: A new imaging probe for prostate cancer
Ronnie C. Mease et al.
CLINICAL CANCER RESEARCH (2008)
Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent
Mark S. Dennis et al.
CANCER RESEARCH (2007)
Progress in the discovery and development of glutamate carboxypeptidase II inhibitors
Takashi Tsukamoto et al.
DRUG DISCOVERY TODAY (2007)
Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen
DS Ma et al.
CLINICAL CANCER RESEARCH (2006)
Technology Insight: monoclonal antibody imaging of prostate cancer
NH Bander
NATURE CLINICAL PRACTICE UROLOGY (2006)
NAAG peptidase inhibitors and their potential for diagnosis and therapy
J Zhou et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies:: Effect of multiple treatments on myelotoxicity
S Vallabhajosula et al.
CLINICAL CANCER RESEARCH (2005)
Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer
NH Bander et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: Efficacy as analgesic agents
AP Kozikowski et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and plouse prostate-specific membrane antigen
XM Huang et al.
PROSTATE (2004)
Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II:: Discovery of an orally active GCP II inhibitor
P Majer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin
L Borsi et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Kinetics and inhibition of glutamate carboxypeptidase II using a microplate assay
C Rojas et al.
ANALYTICAL BIOCHEMISTRY (2002)
分享论文
